AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31631961 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinomax
Number of subjects: 470
Study 31632000 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin
Number of subjects: 0
Study 31632154 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release guaifenesin 1200 mg (Mucinex)
Number of subjects: 552
Study 31632285 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 0
Study 31632316 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin administration
Number of subjects: 0
Study 31632316 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31632387 — intervention group
Group type: EXPERIMENTAL
Intervention: Agonistic autoantibodies (agAAb) activating the β2-adrenergic receptor
Number of subjects: 0
Study 31633999 — intervention group
Group type: EXPERIMENTAL
Intervention: Data quality control strategy applied to clinically relevant parameters
Number of subjects: 300
Study 31633999 — intervention group
Group type: EXPERIMENTAL
Intervention: Data quality control strategy applied to established prognosticators
Number of subjects: 300
Study 31634044 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM vaccine
Number of subjects: 3939
Study 31634236 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy following endotracheal intubation
Number of subjects: 100
Study 31634407 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation (PNS) therapy
Number of subjects: 109
Study 31634515 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 30 daily sessions
Number of subjects: 17
Study 31634515 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 17
Study 31635961 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual segmentation and three-dimensional modeling software for renal volume measurement
Number of subjects: 85
Study 31635961 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal volume measurement
Number of subjects: 85
Study 31635961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of total renal volume (TRV)
Number of subjects: 85
Study 31636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lymphedema undergoing complete decongestive therapy
Number of subjects: 43
Study 31636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower limb lymphedema
Number of subjects: 43
Study 31636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with upper limb lymphedema
Number of subjects: 43
Study 31636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA
Number of subjects: 43
Study 31636050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lymphedema
Number of subjects: 43
Study 31636081 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusion capacity for carbon monoxide and nitric oxide
Number of subjects: 16
Study 31636081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced changes in arterial oxygen
Number of subjects: 16
Study 31636081 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal muscle oxidation
Number of subjects: 16
Study 31636081 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy control subjects
Number of subjects: 16
Study 31636342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab; specific dosage and duration not available
Number of subjects: 0
Study 31636690 — intervention group
Group type: EXPERIMENTAL
Intervention: WSP-EN (white sweet potato enteral nutrition formula)
Number of subjects: 54
Study 31636690 — intervention group
Group type: COMPARATOR
Intervention: Non-WSP-EN (standard polymeric formulas)
Number of subjects: 54
Study 31636713 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 1075
Study 31636713 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (SA)
Number of subjects: 1075
Study 31636713 — intervention group
Group type: COMPARATOR
Intervention: Comparison between EA and SA
Number of subjects: 1075
Study 31636770 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS questionnaire (Canadian French version)
Number of subjects: 147
Study 31636770 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS questionnaire, Short Form-36 (SF-36), St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 147
Study 31637366 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent perceptions of child-level food security status via the 8-item child-referenced Household Food Security Survey Module
Number of subjects: 2408
Study 31637366 — intervention group
Group type: EXPERIMENTAL
Intervention: Child perceptions of child-level food security status via the 5-item Child Food Security Assessment
Number of subjects: 2408
Study 31637440 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D with IAH (n=10)
Number of subjects: 40
Study 31637440 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D with NAH (n=12)
Number of subjects: 40
Study 31637440 — intervention group
Group type: COMPARATOR
Intervention: HC (n=18)
Number of subjects: 40
Study 31637440 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D-IAH (n=10)
Number of subjects: 40
Study 31637440 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D-NAH (n=12)
Number of subjects: 40
Study 31637669 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (tablet 100 mg bid days 3-12) combined with carboplatin (AUC 4) and paclitaxel (175 mg/m2)
Number of subjects: 132
Study 31637669 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (capsule and tablet formulations) using intermittent schedules (2 to 10 days of a 21-day cycle) combined with carboplatin/paclitaxel
Number of subjects: 132
Study 31637669 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib combined with carboplatin/paclitaxel
Number of subjects: 132
Study 31638578 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde PCI
Number of subjects: 4201
Study 31638578 — intervention group
Group type: COMPARATOR
Intervention: Antegrade-only PCI
Number of subjects: 4201
Study 31638652 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 15 mg
Number of subjects: 25000
Study 31638652 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran 110 mg
Number of subjects: 25000
Study 31638652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 25000
Study 31638915 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-adapted Depression Education Intervention (DEI)
Number of subjects: 350
Study 31638967 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Process Assessment Tool (IPAT)
Number of subjects: 0
Study 31639033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue fecal microbiota transplantation (FMT)
Number of subjects: 18
Study 31639039 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C) at doses of 10 mg/kg to 20 mg/kg every 2 weeks until disease progression or intolerable side effects
Number of subjects: 8
Study 31639039 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Number of subjects: 8
Study 31639054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ) with a cut-off of 750 for common mental disorders (depression and anxiety)
Number of subjects: 0
Study 31639054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Recent Life Changes Questionnaire (RLCQ) with a cut-off of 800 for serious mental disorders (suicide, bipolar, dysthymia)
Number of subjects: 0
Study 31639054 — intervention group
Group type: COMPARATOR
Intervention: Agreement between two psychologists using the Mini International Neuropsychiatric Interview (MINI)
Number of subjects: 0
Study 31639066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated whole abdominal radiotherapy (WART)
Number of subjects: 20
Study 31639132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenic patients
Number of subjects: 83
Study 31639692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant 4D4 (L3-2) antibody-assisted assay
Number of subjects: 105
Study 31639692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated nPSA (CN)
Number of subjects: 105
Study 31639692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant 4D4 (L3-2) assay
Number of subjects: 105
Study 31639692 — intervention group
Group type: COMPARATOR
Intervention: Reference wild-type (wt)-4D4-based assays
Number of subjects: 105
Study 31640456 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer (n=37)
Number of subjects: 118
Study 31640456 — intervention group
Group type: COMPARATOR
Intervention: Patients without cancer (n=81)
Number of subjects: 118
Study 31640466 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque erosion diagnosis
Number of subjects: 1241
Study 31640466 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation-ACS
Number of subjects: 1241
Study 31640565 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient-controlled intravenous analgesia (PCIA) with 0.2 mg/kg hydromorphone and 4 mg/kg flurbiprofen; pump programmed as 2.0 mL/h background infusion with a loading dose of 1 mL and a lockout period of 15 min
Number of subjects: 168
Study 31640565 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patient-controlled intravenous analgesia (PCIA)
Number of subjects: 168
Study 31640565 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain status at 4 weeks
Number of subjects: 168
Study 31640594 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-life 25(OH) D concentrations
Number of subjects: 13039
Study 31640726 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural course of unruptured intracranial aneurysms (UIAs)
Number of subjects: 5000
Study 31640726 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for rupture of UIAs
Number of subjects: 5000
Study 31640741 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 0.454% w/w stannous fluoride (1100 ppm fluoride), used twice daily for 24 weeks
Number of subjects: 75
Study 31641390 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncoxin (ONCX)
Number of subjects: 133
Study 31641390 — intervention group
Group type: COMPARATOR
Intervention: Control (CT only)
Number of subjects: 133
Study 31641582 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome analysis of the nasopharynx and oropharynx
Number of subjects: 10
Study 31641633 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin as add-on to metformin
Number of subjects: 1109
Study 31641952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 100
Study 31642041 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular kit (EuSepScreen lattanti)
Number of subjects: 69
Study 31642041 — intervention group
Group type: COMPARATOR
Intervention: Blood culture (BC)
Number of subjects: 69
Study 31642045 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 646
Study 31642045 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 646
Study 31642213 — intervention group
Group type: EXPERIMENTAL
Intervention: SS (SYNTAX Score)
Number of subjects: 1248
Study 31642213 — intervention group
Group type: EXPERIMENTAL
Intervention: SS II (SYNTAX Score II)
Number of subjects: 1248
Study 31642446 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3)
Number of subjects: 117
Study 31642446 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble ST2 (sST2)
Number of subjects: 117
Study 31642446 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2
Number of subjects: 117
Study 31642446 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3 (Gal-3) and soluble ST2 (sST2)
Number of subjects: 117
Study 31642446 — intervention group
Group type: COMPARATOR
Intervention: Primary endpoint (CV death or HF hospitalization)
Number of subjects: 117
Study 31642523 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HA
Number of subjects: 809
Study 31642523 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-C3
Number of subjects: 809
Study 31642523 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 809
Study 31642899 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 1003
Study 31642902 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated T2DM
Number of subjects: 193
Study 31642902 — intervention group
Group type: COMPARATOR
Intervention: T2DM with albuminuria
Number of subjects: 193
Study 31642902 — intervention group
Group type: COMPARATOR
Intervention: T2DM with retinopathy
Number of subjects: 193
Study 31642983 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 100 kcal from sugar per day
Number of subjects: 809
Study 31644329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 39
Study 31644328 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-based treatment stratification after induction treatment
Number of subjects: 0
Study 31644328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment directly after induction for very poor responders
Number of subjects: 0
Study 31644380 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban Zen Integrative Therapy
Number of subjects: 0
Study 31644380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31644538 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt insertion
Number of subjects: 89
Study 31644841 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential Avoidance (EA)
Number of subjects: 183
Study 31645407 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) in patients with diabetes
Number of subjects: 3535
Study 31645407 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) in patients without diabetes
Number of subjects: 3535
Study 31645991 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 SMS behaviour change communication messages
Number of subjects: 0
Study 31645991 — intervention group
Group type: EXPERIMENTAL
Intervention: eVoucher for return transportation to CCS plus the same 15 SMS
Number of subjects: 0
Study 31645991 — intervention group
Group type: COMPARATOR
Intervention: One SMS informing about the nearest CCS clinic
Number of subjects: 0
Study 31646098 — intervention group
Group type: EXPERIMENTAL
Intervention: tremelimumab and interferon-α (IFN)
Number of subjects: 33
Study 31646195 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm newborns with bronchopulmonary dysplasia (BPD)
Number of subjects: 83
Study 31646195 — intervention group
Group type: COMPARATOR
Intervention: Preterm newborns without bronchopulmonary dysplasia (BPD)
Number of subjects: 83
Study 31646200 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal pH measurement
Number of subjects: 100
Study 31646214 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 0
Study 31646214 — intervention group
Group type: COMPARATOR
Intervention: Usual health plan outreach
Number of subjects: 0
Study 31646465 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (8-week regimen)
Number of subjects: 230
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy for 1 year
Number of subjects: 1
Study 31647026 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1
Study 31647026 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-carboplatin-iniparib (GCI)
Number of subjects: 1
Study 31647026 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (XRT)
Number of subjects: 1
Study 31647026 — intervention group
Group type: COMPARATOR
Intervention: Experimental vaccine
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor mutational burden
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: TiME biomarkers (CD8, ICs, PD-L1 on IC)
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related RNA signatures
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBC subtyping
Number of subjects: 1
Study 31647026 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling
Number of subjects: 1
Study 31647326 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31647530 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiogram (SAECG) in Group 1 (patients with BrS)
Number of subjects: 250
Study 31647861 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl isothiocyanate (BITC)
Number of subjects: 0
Study 31648294 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-directed chimeric antigen receptor-modified T (CAR-T) cells, 2 × 10^6 cells per kilogram after lymphodepletion with cyclophosphamide and fludarabine
Number of subjects: 21
Study 31648325 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab treatment
Number of subjects: 90
Study 31648761 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded iFR pull back after angiographically successful PCI
Number of subjects: 500
Study 31648999 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib at the dose of 80 mg/d
Number of subjects: 150
Study 31649017 — intervention group
Group type: EXPERIMENTAL
Intervention: Household contacts exposed to multidrug resistant tuberculosis
Number of subjects: 10160
Study 31649017 — intervention group
Group type: COMPARATOR
Intervention: Household contacts exposed to drug sensitive tuberculosis
Number of subjects: 10160
Study 31649025 — intervention group
Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis (TAK)
Number of subjects: 110
Study 31649025 — intervention group
Group type: COMPARATOR
Intervention: Giant cell arteritis (GCA)
Number of subjects: 110
Study 31649025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TAK and GCA
Number of subjects: 110
Study 31650066 — intervention group
Group type: EXPERIMENTAL
Intervention: TetMYB vaccine
Number of subjects: 32
Study 31650066 — intervention group
Group type: EXPERIMENTAL
Intervention: TetMYB vaccine and Anti-PD-1 antibody
Number of subjects: 32
Study 31650067 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tai Chi Qigong intervention (TCQ)
Number of subjects: 166
Study 31650067 — intervention group
Group type: COMPARATOR
Intervention: Intensity-matched body training intervention (BT)
Number of subjects: 166
Study 31650067 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 166
Study 31650077 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative combination intervention to improve access to pediatric cancer services and treatment adherence
Number of subjects: 0
Study 31650077 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31650161 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Albumin (GA)
Number of subjects: 150
Study 31650161 — intervention group
Group type: COMPARATOR
Intervention: Fructosamine
Number of subjects: 150
Study 31650176 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (HD-Cy) (3 g/m2)
Number of subjects: 25
Study 31650176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (LD-Cy) (≤1.5 g/m2)
Number of subjects: 25
Study 31650176 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T-cell therapy
Number of subjects: 25
Study 31650176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensity of conditioning chemotherapy and minimal pretreatment disease burden
Number of subjects: 25
Study 31650393 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 929
Study 31650393 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, diabetes duration, BMI, HbA1c, use of metformin, sulfonylurea derivatives, and DPP4 inhibitors
Number of subjects: 929
Study 31650393 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol and serum creatinine
Number of subjects: 929
Study 31650889 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat interpretation bias
Number of subjects: 0
Study 31650889 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign interpretation bias
Number of subjects: 0
Study 31650889 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences
Number of subjects: 0
Study 31651050 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel subjected to pressure on mattress
Number of subjects: 18
Study 31651050 — intervention group
Group type: COMPARATOR
Intervention: Heel protected by pillow
Number of subjects: 18
Study 31651098 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable PrEP
Number of subjects: 136
Study 31651278 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia Etiology in Ethiopia (AnemEE) survey
Number of subjects: 0
Study 31651278 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated interventions (e.g., iron fortification)
Number of subjects: 0
Study 31651359 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenous infusion every 2 weeks (1 L subgroup)
Number of subjects: 82
Study 31651359 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenous infusion every 2 weeks (2 L subgroup)
Number of subjects: 82
Study 31651364 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized oral care bundle (oral assessment, tooth brushing, moisturization, and secretion removal)
Number of subjects: 4200
Study 31651364 — intervention group
Group type: COMPARATOR
Intervention: Oral chlorhexidine
Number of subjects: 4200
Study 31651363 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 SPEAR T cells with fludarabine-containing conditioning regimen
Number of subjects: 42
Study 31651363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine-containing conditioning regimen
Number of subjects: 42
Study 31651363 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 SPEAR T cells
Number of subjects: 42
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) use
Number of subjects: 15092
Study 31651951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs) use
Number of subjects: 15092